<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83313">
  <stage>Registered</stage>
  <submitdate>30/10/2008</submitdate>
  <approvaldate>15/09/2009</approvaldate>
  <actrnumber>ACTRN12609000800224</actrnumber>
  <trial_identification>
    <studytitle>Observational study to determine the type of patient with cervical dystonia that responds best to botulinum toxin treatment</studytitle>
    <scientifictitle>An international observational study to define factors influencing response to one Botulinum Toxin Type A (BoNT-A) injection cycle in subjects suffering from idiopathic cervical dystonia.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Y-79-52120-131. Ipsen.</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Idiopathic Cervical Dystonia</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Botulinum Toxin Type A (BoNT-A) for idiopathic cervical dystonia.  BoNT-A is able to stop nerves stimulating muscles thus providing a way of relaxing muscles.  BoNT-A is administered by intramuscular injections with a duration of action of between 12 to 16 weeks.  Observations will be made at 3-6 weeks post injection and again at the time of re-injection (12-16 weeks).  The dosage given to the patient will be at the clinician's discretion.</interventions>
    <comparator>Not Applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To estimate the responder rate at peak effect following one BoNT-A injection cycle.  Responders will be defined as those that have a clinically signficant improvement in severity of dystonia (medical assessment) with no safety issues (medical observations).</outcome>
      <timepoint>The outcome will be assessed at some time between 3-6 weeks post-injection according to patient and clinician availability.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Head and Neck Deviations by medical assessment/test.</outcome>
      <timepoint>Assessments will be undertaken 3-6 weeks and 12-16 weeks post injection according to patient and clinician availability.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toronto Western Spasmodic Torticollis Rating Scale (TWSTR).</outcome>
      <timepoint>Assessment will be undertaken 3-6 weeks and 12-16 weeks post injection according to patient and clinician availability.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tremor (from TSUI scale)</outcome>
      <timepoint>Assessment will be undertaken 3-6 weeks and 12-16 weeks post injection according to patient and clinician availability.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Cervical Dystonia Impact Profile (CDIP-58).</outcome>
      <timepoint>Assessment will be undertaken 3-6 weeks post injection according to patient and clinician availability.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Global Improvement (single question questionnaire)</outcome>
      <timepoint>Assessment will be undertaken 3-6 weeks post injection according to patient and clinician availability.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Greater than or equal to 18 years of age with idiopathic cervical dystonia.  Toronto Western Spasmodic Torticollis Rating Scale score of greater than or equal to 15 and at least 12 weeks since last BoNT-A Injection.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Contraindication to BoNT-A 
Secondary cervical dystonia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>24/02/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ipsen</primarysponsorname>
    <primarysponsoraddress>Suite 6 Montclair Ave, Glen Waverley, VIC 3150</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ipsen</fundingname>
      <fundingaddress>Suite 6 Montclair Ave, Glen Waverley, VIC 3150</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to determine which patients who suffer from cervical dystonia respond the best to botulinum toxin treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney West Area Health Service</ethicname>
      <ethicaddress>Westmead Hospital
Hawkesbury Road
Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate>5/03/2009</ethicapprovaldate>
      <hrec>1/09</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>Alfred Hospital
Commercial Road
Prahran
VIC 3181</ethicaddress>
      <ethicapprovaldate>11/03/2009</ethicapprovaldate>
      <hrec>2008/12/4.6</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Melbourne Human Research Ethics</ethicname>
      <ethicaddress>St Vincent's Hospital
Victoria Parade
Fitzroy Vic 3065</ethicaddress>
      <ethicapprovaldate>15/01/2009</ethicapprovaldate>
      <hrec>162/08</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Austin Hospital
145 Studley Road
Heidelberg, Vic 3084</ethicaddress>
      <ethicapprovaldate>26/02/2009</ethicapprovaldate>
      <hrec>H2009/03467</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Monica de Abadal</name>
      <address>PO Box 820 Glen Waverley, Vic, 3150</address>
      <phone>+61 3 85448100</phone>
      <fax />
      <email>monica.deabadal@ipsen.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Angela Gibbs</name>
      <address>PO Box 820 Glen Waverley, Vic, 3150</address>
      <phone>+61 3 85448100</phone>
      <fax />
      <email>angela.gibbs@ipsen.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Angela Gibbs</name>
      <address>PO Box 820 Glen Waverley, Vic, 3150</address>
      <phone>+61 3 85448100</phone>
      <fax />
      <email>angela.gibbs@ipsen.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>